For following the competition: what moved in each program, several studies read as one move.
- daraxonrasib
- zoldonrasib
- KRAS G12V Inhibitor RMC-5127
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Revolution Medicines to watchlistEvery Monday by email · turn it off any timePro · free during the beta